The Lynx Group

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent — May 28, 2020
In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read Article

Conference Correspondent — May 28, 2020
Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Read Article

Conference Correspondent — May 28, 2020
The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.
Read Article

Conference Correspondent — May 28, 2020
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read Article

Conference Correspondent — May 28, 2020
Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.
Read Article

Conference Correspondent — May 28, 2020
Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.
Read Article

Conference Correspondent — March 20, 2020
Insights about real-world clinical experience with new drugs, such as acalabrutinib, are highly valuable. At ASH 2019, researchers evaluated acalabrutinib use in real-world patients with mantle-cell lymphoma and chronic lymphocytic leukemia.
Read Article

Conference Correspondent — March 20, 2020
Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes.
Read Article

Conference Correspondent — March 20, 2020
Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma.
Read Article

Conference Correspondent — March 20, 2020
Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read Article

Page 1 of 35

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: